Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma
Not available.
Saved in:
Main Authors: | Julia Wendler, Richard I. Lewis, Alexandra Kutilina, Markus Knott, Lisa Kristina Isbell, Elke Valk, Peter Borchmann, Jan-Michel Heger, Gerald Illerhaus, Elisabeth Schorb |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-01-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/11907 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High-Dose Methotrexate for the Treatment of Relapsed Central Nervous System Erdheim-Chester Disease
by: Prahlad Ho, et al.
Published: (2014-01-01) -
Rituximab Monotherapy versus Rituximab and
Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy
by: Arash Maleki, et al.
Published: (2022-11-01) -
The predictors of successful methotrexate treatment of tubal ectopic pregnancy
by: Eiman Abdelfattah-Arafa, et al.
Published: (2024-12-01) -
The Value of Hysterosalpingography following Medical Treatment with Methotrexate for Ectopic Pregnancy
by: Emma Garcia Grau, et al.
Published: (2011-01-01) -
An Experimental Study: Benefits of Digoxin on Hepatotoxicity Induced by Methotrexate Treatment
by: Banu Taskin, et al.
Published: (2021-01-01)